Retatrutide hit 30% weight loss. The grey market already sells it. ($LLY)

The pricing decision is where Lilly’s next leg of obesity dominance is won or lost - and it has a competitor most analysts are not pricing in.

Introduction

Lilly closed June 8 at an all-time high of $1,182.73, up about 4% on the day, carrying a market capitalization near $1.1 trillion. The catalyst was the company’s ADA investor event and the first Phase 3 look at retatrutide. The reaction was in many ways expected, overwhelmingly positive, bordering on ecstatic. Retatrutide is the best obesity…